We celebrated the retirement of 2 #Hematology pioneers this weekend. Dr Brian Leber and Dr Irwin Walker have left their mark not only locally but across Canada. Thank you! #hemepioneers
Elephants rarely get cancer. Why? @MrinalPatnaik explained the reasons at the @eaonc meeting today.
They have 40 copies of the p53 tumor suppressor gene. (Humans have 2 copies)
Let’s test your knowledge! How many different ways can you donate stem cells?
ANSWER: 3! 80% of people donate through the PBSC method, which is similar to donating blood.
For other frequently asked questions, and to register to donate stem cells, visit https://t.co/TVbHDDj3XU
Our traditional 41st BMT / Survivorship Picnic! We celebrated patients and caregivers through their journeys in allogeneic stem cell transplant on September 14. Amazing to see and spend time with our great transplant community!
@HamHealthSci@machealthsci@hamhealth@CTTC_ORG
Today, Canadian Blood Services delivered an apology to 2SLGBTQIA+ communities. This is a necessary step in our ongoing journey to make our policies/processes & all interactions with CBS more inclusive for 2SLGBTQIA+ communities.
Learn more: https://t.co/pO1CWb3QNr
As we get closer to the end of the #LatinAmericaHeritageMonth in #Canada... a few lines about our history in this country:
The majority of Latin American Canadians are recent immigrants who arrived in the late 20th century 1/4
Out in @TheLancetHaem, our Correspondence on AMLSG 09–09 by Döhner et al.
1/🚩The AMLSG09-09 study added gemtuzumab ozagamicin (GO) to chemo in patients w/ NPM1-mutated AML. Despite no ΔOS/EFS, authors conclude young patients benefit due to lower relapse rates. We're skeptical🤔
FDA approves quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation for newly diagnosed acute myeloid leukemia (#AML). Drug label: https://t.co/fxICQvNqnk
If you’re between 17 and 35, you could become someone’s match by joining the Canadian Blood Services Stem Cell Registry. Currently, people who are Black, Indigenous, Asian, Hispanic or mixed-race make up only about a third of registrants.
Read more at https://t.co/IOGzhWfH2F
An incredible amount of work with really brilliant people made #BMTCTN1703 a success and the new SOC for #GvHD prophylaxis #PTCyRules#BMTCTN@CIBMTR Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis | NEJM https://t.co/qXN7YxG5g4
A simple scoring system, key to aid clinicians and patients in clinical decision-making
👇
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups https://t.co/zaHkxPsfJ0